Home / Business and Economy / Mobia Medical's Revenue Skyrockets Over 100% on Therapy Adoption
Mobia Medical's Revenue Skyrockets Over 100% on Therapy Adoption
12 Aug
Summary
- Mobia Medical reported Q2 revenue of $13.5 million, a 102% increase year-over-year.
- The company initiated full-year 2026 revenue guidance between $54-$56 million.
- Vivistim therapy, approved for stroke survivors, supports neuroplasticity and motor pathway recovery.
Mobia Medical announced impressive second-quarter financial results, with revenue climbing to $13.5 million, marking a substantial 102% increase compared to $6.7 million in the prior year. This growth was driven by the wider acceptance of its Vivistim paired vagus nerve stimulation therapy in stroke rehabilitation programs.
During its first earnings call as a public company, Mobia Medical revealed its full-year 2026 revenue forecast, projecting between $54 million and $56 million. This guidance suggests an anticipated growth rate of 69% to 75% over the 2025 fiscal year.
The Vivistim system, cleared by the FDA, is designed for chronic stroke survivors experiencing moderate to severe upper-limb impairments. It stimulates the vagus nerve during specific exercises to promote neuroplasticity and aid in the formation of new neural connections.
The company observed a 92% rise in active territories to 35.5 during the quarter. Mobia's commercial strategy involves engaging stroke hospitals through dedicated territory managers and therapy development specialists, who are typically licensed therapists.
